NCT00062504终止2 期
A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 30
研究概览
简要总结
To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas.
详细描述
To determine the efficacy of Talampanel in patients with recurrent malignant glioma as measured by 6-month progression survival, as well as to obtain preliminary information regarding the spectrum of toxicities of the drug among this patient population.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
Valproic: 10mg TID week 1, 25mg TID week 2, 35mg week 3
干预措施: Talampanel (Drug)
2
Experimental
Non-enzyme-inducing anti-epileptic drugs: 25mg TID week 1, 35mg week 2, 50mg week 3
干预措施: Talampanel (Drug)
3
Experimental
Enzyme-inducing anti-epileptic drugs: 35mg TID week 1, 505mg week 2, 75mg week 3
干预措施: Talampanel (Drug)
研究者
相似试验
已完成
2 期
Safety and Efficacy of Talampanel in Glioblastoma MultiformeGlioblastoma MultiformeNCT00267592Teva Branded Pharmaceutical Products R&D, Inc.72
已完成
2 期
A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction CancerGastric CancerNCT01983878Eli Lilly and Company36
已完成
2 期
Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck CancerHead and Neck CancerNCT00003850National Cancer Institute (NCI)47
已完成
2 期
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaB-cell Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaNCT00006226National Cancer Institute (NCI)41
已完成
2 期
Gleevec Study for Patients With Ovarian CancerOvarian CancerNCT00510653M.D. Anderson Cancer Center73